 Sarit Polsky
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy in Diabetics | 23 | 2025 | 123 | 13.280 |
Why?
| | Diabetes Mellitus, Type 1 | 50 | 2025 | 3715 | 6.920 |
Why?
| | Blood Glucose Self-Monitoring | 30 | 2025 | 641 | 6.080 |
Why?
| | Insulin Infusion Systems | 18 | 2025 | 394 | 6.000 |
Why?
| | Blood Glucose | 39 | 2025 | 2186 | 5.690 |
Why?
| | Hypoglycemic Agents | 20 | 2025 | 1291 | 4.690 |
Why?
| | Insulin | 21 | 2025 | 2409 | 3.740 |
Why?
| | Pregnancy | 32 | 2025 | 6763 | 2.150 |
Why?
| | Hypoglycemia | 8 | 2025 | 445 | 1.640 |
Why?
| | Diabetes, Gestational | 6 | 2024 | 318 | 1.610 |
Why?
| | Pregnancy Outcome | 11 | 2025 | 416 | 1.460 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 201 | 1.270 |
Why?
| | Female | 55 | 2025 | 73304 | 0.950 |
Why?
| | Ketones | 1 | 2025 | 49 | 0.930 |
Why?
| | Alcohol Drinking | 4 | 2020 | 828 | 0.850 |
Why?
| | Adult | 40 | 2025 | 37929 | 0.840 |
Why?
| | Postnatal Care | 2 | 2021 | 71 | 0.790 |
Why?
| | Humans | 67 | 2025 | 137585 | 0.740 |
Why?
| | Pilot Projects | 6 | 2024 | 1710 | 0.690 |
Why?
| | Diabetes Complications | 2 | 2020 | 227 | 0.680 |
Why?
| | Preconception Care | 1 | 2021 | 43 | 0.680 |
Why?
| | Diabetes Mellitus, Type 2 | 8 | 2024 | 2531 | 0.620 |
Why?
| | Young Adult | 18 | 2025 | 13209 | 0.600 |
Why?
| | Tobacco Use | 1 | 2018 | 64 | 0.560 |
Why?
| | Spices | 2 | 2014 | 5 | 0.560 |
Why?
| | Hyperglycemia | 4 | 2022 | 347 | 0.530 |
Why?
| | Postprandial Period | 2 | 2019 | 107 | 0.520 |
Why?
| | Fear | 1 | 2019 | 338 | 0.510 |
Why?
| | Food Preferences | 2 | 2014 | 119 | 0.510 |
Why?
| | Quality of Life | 3 | 2025 | 2892 | 0.500 |
Why?
| | Obesity | 5 | 2019 | 2992 | 0.460 |
Why?
| | Lunch | 1 | 2014 | 7 | 0.460 |
Why?
| | Meat Products | 1 | 2014 | 25 | 0.450 |
Why?
| | Breakfast | 1 | 2014 | 20 | 0.450 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2111 | 0.420 |
Why?
| | Postoperative Care | 1 | 2015 | 261 | 0.410 |
Why?
| | Insulin Resistance | 3 | 2022 | 1208 | 0.390 |
Why?
| | Preoperative Care | 1 | 2015 | 362 | 0.390 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 1040 | 0.380 |
Why?
| | Infant, Newborn | 5 | 2024 | 6079 | 0.380 |
Why?
| | Diabetic Nephropathies | 3 | 2020 | 294 | 0.370 |
Why?
| | Comorbidity | 2 | 2021 | 1622 | 0.360 |
Why?
| | Hypertension | 1 | 2020 | 1295 | 0.360 |
Why?
| | Bariatric Surgery | 1 | 2015 | 217 | 0.360 |
Why?
| | Insulin Aspart | 2 | 2022 | 27 | 0.360 |
Why?
| | Retrospective Studies | 12 | 2025 | 15657 | 0.350 |
Why?
| | Uric Acid | 3 | 2022 | 163 | 0.340 |
Why?
| | Diabetic Neuropathies | 2 | 2022 | 94 | 0.330 |
Why?
| | Weight Loss | 4 | 2019 | 787 | 0.330 |
Why?
| | Postpartum Period | 2 | 2025 | 340 | 0.330 |
Why?
| | Allopurinol | 2 | 2020 | 63 | 0.320 |
Why?
| | Glomerular Filtration Rate | 4 | 2022 | 746 | 0.310 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 1083 | 0.310 |
Why?
| | Monitoring, Physiologic | 2 | 2025 | 275 | 0.310 |
Why?
| | Feeding Behavior | 1 | 2014 | 654 | 0.300 |
Why?
| | Prediabetic State | 1 | 2011 | 253 | 0.280 |
Why?
| | Cross-Over Studies | 3 | 2024 | 564 | 0.260 |
Why?
| | Prenatal Care | 2 | 2021 | 294 | 0.250 |
Why?
| | Middle Aged | 21 | 2024 | 33479 | 0.240 |
Why?
| | Feasibility Studies | 2 | 2024 | 956 | 0.240 |
Why?
| | United States | 9 | 2024 | 14841 | 0.240 |
Why?
| | Gastric Bypass | 2 | 2019 | 119 | 0.240 |
Why?
| | Risk Factors | 10 | 2022 | 10388 | 0.230 |
Why?
| | Pancreas, Artificial | 3 | 2025 | 84 | 0.220 |
Why?
| | Cost Savings | 1 | 2024 | 84 | 0.220 |
Why?
| | Hospitalization | 3 | 2024 | 2199 | 0.220 |
Why?
| | Labor, Obstetric | 1 | 2024 | 61 | 0.210 |
Why?
| | Registries | 4 | 2020 | 2035 | 0.210 |
Why?
| | Weight Reduction Programs | 2 | 2015 | 117 | 0.210 |
Why?
| | Single-Blind Method | 1 | 2024 | 282 | 0.210 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 144 | 0.200 |
Why?
| | Biomedical Technology | 1 | 2023 | 43 | 0.200 |
Why?
| | Off-Label Use | 1 | 2023 | 52 | 0.200 |
Why?
| | Male | 23 | 2024 | 67762 | 0.200 |
Why?
| | Insulin Lispro | 1 | 2022 | 39 | 0.190 |
Why?
| | Patient Admission | 1 | 2024 | 197 | 0.190 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 591 | 0.190 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 36 | 0.180 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 189 | 0.180 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.180 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 257 | 0.180 |
Why?
| | Aged | 14 | 2022 | 23961 | 0.180 |
Why?
| | Technology | 1 | 2021 | 96 | 0.180 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 186 | 0.170 |
Why?
| | Patient Satisfaction | 1 | 2025 | 660 | 0.170 |
Why?
| | Parity | 1 | 2020 | 126 | 0.170 |
Why?
| | Adolescent | 10 | 2024 | 21513 | 0.170 |
Why?
| | Xanthine Oxidase | 1 | 2020 | 81 | 0.160 |
Why?
| | Overweight | 2 | 2015 | 558 | 0.160 |
Why?
| | Epidemics | 1 | 2021 | 89 | 0.160 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 23 | 0.160 |
Why?
| | Appetite Regulation | 1 | 2019 | 31 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2844 | 0.150 |
Why?
| | Diet, Reducing | 1 | 2019 | 89 | 0.150 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 236 | 0.140 |
Why?
| | Sleep | 1 | 2024 | 755 | 0.140 |
Why?
| | Eczema | 1 | 2018 | 69 | 0.140 |
Why?
| | Treatment Outcome | 4 | 2021 | 10811 | 0.140 |
Why?
| | Telemetry | 1 | 2017 | 40 | 0.130 |
Why?
| | Insulin, Short-Acting | 1 | 2016 | 6 | 0.130 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 840 | 0.130 |
Why?
| | Double-Blind Method | 4 | 2024 | 1993 | 0.130 |
Why?
| | Glucose | 1 | 2021 | 1020 | 0.130 |
Why?
| | Infusions, Subcutaneous | 1 | 2016 | 23 | 0.130 |
Why?
| | HIV Infections | 1 | 2011 | 2836 | 0.120 |
Why?
| | Sex Characteristics | 2 | 2018 | 762 | 0.120 |
Why?
| | Self Care | 1 | 2018 | 380 | 0.120 |
Why?
| | Taste | 2 | 2014 | 229 | 0.120 |
Why?
| | Albuminuria | 3 | 2022 | 185 | 0.120 |
Why?
| | Cheese | 1 | 2014 | 6 | 0.110 |
Why?
| | Gastroplasty | 1 | 2014 | 30 | 0.110 |
Why?
| | Body Mass Index | 3 | 2019 | 2389 | 0.110 |
Why?
| | Pleasure | 1 | 2014 | 19 | 0.110 |
Why?
| | Chickens | 1 | 2014 | 191 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 628 | 0.110 |
Why?
| | Life Style | 2 | 2023 | 490 | 0.110 |
Why?
| | Vegetables | 1 | 2014 | 157 | 0.100 |
Why?
| | Delphi Technique | 1 | 2015 | 280 | 0.100 |
Why?
| | Skin | 1 | 2018 | 752 | 0.100 |
Why?
| | Menopause | 1 | 2016 | 320 | 0.100 |
Why?
| | Community Health Services | 1 | 2014 | 227 | 0.100 |
Why?
| | Models, Organizational | 1 | 2013 | 151 | 0.100 |
Why?
| | Program Evaluation | 2 | 2014 | 898 | 0.100 |
Why?
| | Glucose Tolerance Test | 2 | 2011 | 366 | 0.100 |
Why?
| | Dietary Fats | 1 | 2014 | 304 | 0.090 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5472 | 0.090 |
Why?
| | Internet | 1 | 2016 | 655 | 0.090 |
Why?
| | Cohort Studies | 3 | 2020 | 5742 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1477 | 0.090 |
Why?
| | Creatinine | 2 | 2022 | 499 | 0.080 |
Why?
| | Laparoscopy | 1 | 2014 | 466 | 0.080 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2022 | 135 | 0.080 |
Why?
| | Renin-Angiotensin System | 2 | 2020 | 85 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2021 | 7635 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3457 | 0.070 |
Why?
| | Child | 6 | 2024 | 21935 | 0.070 |
Why?
| | Diabetic Angiopathies | 2 | 2020 | 259 | 0.070 |
Why?
| | Telemedicine | 1 | 2016 | 862 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2013 | 951 | 0.060 |
Why?
| | Rural Health Services | 1 | 2007 | 128 | 0.060 |
Why?
| | Diet | 1 | 2014 | 1278 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5778 | 0.060 |
Why?
| | Metformin | 1 | 2009 | 331 | 0.060 |
Why?
| | Health Behavior | 1 | 2009 | 762 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 110 | 0.050 |
Why?
| | Bionics | 1 | 2022 | 12 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1639 | 0.050 |
Why?
| | Iohexol | 1 | 2022 | 23 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 30 | 0.050 |
Why?
| | Energy Intake | 2 | 2019 | 485 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.050 |
Why?
| | Demography | 1 | 2021 | 291 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2007 | 758 | 0.040 |
Why?
| | Aspirin | 1 | 2023 | 387 | 0.040 |
Why?
| | Peptide YY | 1 | 2019 | 17 | 0.040 |
Why?
| | Satiation | 1 | 2019 | 24 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2023 | 494 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 356 | 0.040 |
Why?
| | Ghrelin | 1 | 2019 | 36 | 0.040 |
Why?
| | Vascular Stiffness | 1 | 2024 | 494 | 0.040 |
Why?
| | Appetite | 1 | 2019 | 69 | 0.040 |
Why?
| | Sex Factors | 2 | 2018 | 2071 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5131 | 0.040 |
Why?
| | Income | 1 | 2019 | 202 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 672 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 306 | 0.030 |
Why?
| | Population Surveillance | 1 | 2021 | 482 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 470 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2016 | 106 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 642 | 0.030 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 152 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 773 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 688 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1468 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3284 | 0.020 |
Why?
| | Meals | 1 | 2014 | 125 | 0.020 |
Why?
| | Animals | 1 | 2014 | 36940 | 0.020 |
Why?
| | Blood Pressure | 1 | 2019 | 1786 | 0.020 |
Why?
| | Focus Groups | 1 | 2014 | 522 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3295 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2757 | 0.020 |
Why?
| | Health Education | 1 | 2014 | 341 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2014 | 264 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 618 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1972 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 199 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4149 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2009 | 203 | 0.020 |
Why?
| | Glucose Intolerance | 1 | 2009 | 146 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7604 | 0.020 |
Why?
| | Kenya | 1 | 2007 | 118 | 0.020 |
Why?
| | Accidental Falls | 1 | 2007 | 196 | 0.010 |
Why?
| | Violence | 1 | 2007 | 266 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 6828 | 0.010 |
Why?
| | Colorado | 1 | 2014 | 4565 | 0.010 |
Why?
| | Burns | 1 | 2007 | 325 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2014 | 2654 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2804 | 0.010 |
Why?
|
|
Polsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|